Home / Conditions / Obesity (page 4)

Obesity

Obesity and Diabetes: Diabetes patients are considered obese when they have a Body Mass Index over 30. Such patients are at greater risk for a host of other problems cardiovascular disease, cancer, sleep apnea, and poor quality of life. Tremendous research is being done to control, manage, and reverse obesity in diabetics and the educated healthcare professional can help.

GLP-1s and the Gut Microbiome: Emerging Insights Into Gut–Metabolic Interactions

Scientific illustration of GLP-1 receptor activity in the intestinal lining surrounded by diverse gut microbiome bacteria, highlighting gut–metabolic interactions.

The conversation around GLP-1 therapies has shifted quickly. While most clinicians focus on weight loss and glucose lowering, new data on GLP-1 microbiome effects suggest something deeper may be happening in the gut. Could these medications reshape the intestinal ecosystem in ways that support long-term metabolic health? Increasingly, researchers believe …

Read More »

GLP-1s and Reproductive Health: What to Know About Fertility, Pregnancy, and PCOS

Female physician reviewing chart with GLP-1 injection pen in foreground and silhouette of pregnant woman, representing GLP-1 reproductive health and pregnancy considerations

GLP-1 receptor agonists are transforming diabetes and obesity care. However, as more women of reproductive age use medications like semaglutide, liraglutide, and tirzepatide, questions about how GLP-1 therapies affect fertility and pregnancy are becoming increasingly common. Can patients conceive safely while taking these agents? Do they improve ovulation in women …

Read More »

Off-Ramp Planning for GLP-1s: When and How to Taper Without Losing Progress

Physician reviewing a gradual medication dose reduction chart with a patient during a consultation about GLP-1 tapering and metabolic health goals.

As more patients succeed on GLP-1 therapy, conversations about tapering these medications are becoming increasingly common in metabolic care. When patients reach meaningful goals in weight reduction, A1C improvement, or cardiometabolic risk, clinicians naturally begin asking what comes next. Is it safe to stop treatment? More importantly, can progress be …

Read More »

GLP-1s and Food Noise: Helping Patients Understand Hunger, Cravings, and Control

Woman calmly eating a healthy meal while unhealthy foods fade around her, illustrating reduced GLP-1 food noise and improved appetite control.

Patients taking GLP-1 receptor agonists often describe a surprising change: the “volume” of food thoughts seems to turn down. This experience, often described as a reduction in food noise with GLP-1 therapy, reflects measurable neuroendocrine shifts in appetite regulation and reward signaling. For clinicians, understanding and explaining this phenomenon is …

Read More »

GLP-1s in Young Adults: Rethinking Metabolic Risk and Early Intervention

Young adults consulting with a physician about GLP-1 therapy for obesity and early metabolic risk management

For years, GLP-1 receptor agonists have been associated with older adults who already have type 2 diabetes or established cardiovascular disease. However, metabolic dysfunction does not suddenly appear at age 60. In fact, obesity, insulin resistance, and prediabetes often begin decades earlier. That is why conversations around GLP-1 therapy in …

Read More »

Talking About Off‑Label GLP‑1 Use: How to Answer Patients Without Overpromising

Doctor discussing GLP-1 off-label medication options with a patient in a clinical setting, with injection pens and research charts visible.

A patient walks into your exam room, hopeful after reading that a diabetes drug might help with memory loss, addiction, or even anxiety. You know they’re talking about GLP‑1s—but how do you respond when the science is still unfolding? As GLP‑1 receptor agonists capture public attention for much more than …

Read More »

GLP‑1 Stewardship in the Clinic: Prioritizing, Deprescribing, and Switching Without Chaos

Medical concept featuring GLP-1 medication, injection pens, stethoscope, and clinic policy checklists on a desk

What happens when a breakthrough therapy becomes too popular for its own good? Clinics across the country are struggling to manage demand for GLP‑1 receptor agonists amid soaring prescriptions, medication shortages, and shifting insurance coverage. Without a strategy, patients fall through the cracks—and providers are left making chaotic case-by-case decisions. …

Read More »

GLP‑1s on the WHO Radar: Turning Global Guidance Into Everyday Prescribing

GLP‑1 medication pen and stethoscope on a world map with WHO logo in background

What happens when a once-costly, class-specific treatment becomes a global health priority? That’s the question raised by the World Health Organization’s latest move: recognizing GLP‑1 receptor agonists as essential medicines and issuing new recommendations for their use in obesity and diabetes care. These updated GLP‑1 WHO guidelines are more than …

Read More »

Aiming for MASH Resolution: How to Use GLP‑1s in Liver‑First Diabetes Care

A doctor holding a liver model with GLP-1 injection tools, healthy food, and a glucometer, symbolizing GLP‑1 MASH treatment in diabetes care.

What if the key to resolving both diabetes and liver disease lies in a single therapeutic approach? As rates of metabolic dysfunction-associated steatohepatitis (MASH) rise among people with type 2 diabetes, many clinicians are rethinking how they prioritize treatment. Rather than treating glucose and liver health in silos, combining therapies …

Read More »